White blood cell count profile in patients with physical complaints without known causes

Tetsuya Akaishi1, Tadashi Ishii1, Naoki Nakaya2, Tomohiro Nakamura2, Mana Kogure2, Rieko Hatanaka2, Fumi Itabashi2, Ikumi Kanno2, Masashi Aoki3 and Atsushi Hozawa2

Abstract
Objectives: The aim of this study was to search for routine blood test biomarkers in patients with physical symptoms but without a diagnosis after comprehensive routine screening diagnostic examinations.
Methods: A total of 228 adults aged < 65 years who presented with physical complaints without known causes after comprehensive screening diagnostic examinations and 228 age- and sex-matched healthy controls without physical complaints were enrolled. The blood cell count data at the first hospital visit were compared between these groups.
Results: Total white blood cell (p = 0.2143), red blood cell (p = 0.8954), and platelet (p = 0.7716) counts did not differ between the groups. The monocyte count (p = 0.0014) and resultant monocyte-to-lymphocyte ratio (p < 0.0001) were higher in the symptomatic group, while the other white blood cell subtypes did not differ significantly between the two groups. In the symptomatic group, patients with a monocyte-to-lymphocyte ratio > 0.25 were likely to have unexplained nonfocal physical symptoms (p < 0.0001). The characteristic findings included fatigability (p < 0.0001), prolonged slight fever (p = 0.0005), and widespread pain (p < 0.0001). The monocyte-to-lymphocyte ratio level was correlated with the proportion of patients with unexplained nonfocal symptoms.
Conclusion: The blood cell count profile was largely the same between healthy individuals and patients with unexplained physical symptoms. However, patients with unexplained nonfocal physical complaints were likely to show an elevated monocyte-to-lymphocyte ratio, typically > 0.25.

Keywords
Monocyte count, monocyte-to-lymphocyte ratio, physical complaints, white blood cell count

Introduction
Patients with physical complaints without known causes often experience severely annoying physical conditions that can lead to long-term distress. Patients with these complaints and without a diagnosis after comprehensive screening diagnostic tests are often not sufficiently managed,1 possibly due to the absence of reliable laboratory markers for the diagnosis and follow-up of patient conditions. Patients with these complaints are often given a diagnosis of exclusion, such as psychosomatic disorder, somatoform disorder, chronic fatigue syndrome, fibromyalgia, psychogenic fever, irritable bowel syndrome, autonomic nervous system dysfunction, or panic disorders.2-4 Most of these exclusion diagnoses currently lack established disease-specific diagnostic laboratory markers or specific disease mechanisms. Furthermore, some diseases with unknown causes may...
overlap in a single patient, complicating patient management. This study aimed to search for potential routine laboratory biomarkers for use in evaluating and managing the patients with unknown diagnoses after comprehensive screening diagnostic examinations. Thus, we evaluated blood cell counts and their derivatives in patients with unexplained physical symptoms.

**Methods**

**Enrollment**

This study was a retrospective, case-controlled observational study. The design of this study is illustrated in Figure 1. Patients with physical complaints lasting for more than 1 month and who visited the Department of General Medicine of Tohoku University Hospital between April 2018 and March 2021 were initially recruited. From these patients, those who were suffered from unexplained physical complaints lasting for more than 1 month without certain causes after subsequent comprehensive screening tests and diagnostic examinations were included in the following analyses. The exclusion criteria include (1) patients who were later given definite diagnoses based on disease-specific diagnostic objective findings (e.g., laboratory diagnostic markers or organic lesions identified with imaging tests), (2) patients with elevated serum C-reactive protein (CRP) levels ≥ 0.30 mg/dL, and (3) patients who had been already treated by steroids or other immunosuppressants before being consulted to our hospital. Those who were with elevated CRP levels or treated by immunosuppressants were excluded to avoid potential bias in the subsequent analyses using white blood cell (WBC) count could due to possible systemic inflammation of uncertain clinical significance. To compare blood test data, age- and sex-matched healthy volunteers whose blood samples were evaluated at the same university hospital, selected from 2492 healthy volunteers who fulfilled the enrollment criteria in this study, were recruited as the healthy control (HC) group. Propensity score matching was used to select matched control participants, and the age and sex were used as explanatory variables. Propensity scores were calculated using a multivariate logistic regression model. The profile of the entire population of healthy volunteers was reported previously.

**Evaluated data**

Blood cell count data obtained at the first hospital visit, including the total WBC, red blood cell (RBC), platelet, and differential WBC counts for five WBC subtypes (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), were evaluated. Using these specific and differentiated WBC counts, the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were determined according to the following formulas.
In addition to these blood test data, detailed clinical manifestations of patients in the symptomatic group were further investigated. The most common unexplained complaints included fatigability, slight fever (37.0°C–37.9°C), widespread systemic pain, abnormal bowel habits, and cough. Based on the combinations of unexplained physical complaints, the symptomatic group was further divided into patients with unexplained single focal physical complaint, localized to one organ system, and those with nonfocal physical complaints.

Statistical analyses

Based on a priori sample size calculation, a sample of 200 participants in each group was required to detect the weak effect size of $d=0.20$ with a power $(1-\beta)$ of 0.80 and $\alpha=0.05$. The same to detect the moderate effect size of $d=0.50$ with a power of 0.80 and $\alpha=0.05$ was 34 participants in each group. Comparisons of the quantitative variables between the two groups were performed using Student’s t-test or Mann–Whitney U test according to the distribution patterns of the variables. Comparisons of qualitative data between the two groups were performed using the chi-square or Fisher’s exact tests. Comparisons of MLR values for the common nonfocal complaints among the symptomatic patients, together with age- and sex-matched HCs, were performed using analysis of variance (ANOVA), followed by Tukey’s post hoc tests. The correlations between two quantitative variables were evaluated using Spearman’s correlation coefficient ($\rho$), followed by the tests of no correlation. As approximately 10 types of blood cell count and derivatives were simultaneously compared, $p<0.005$ was considered statistically significant. To visually confirm the different profiles of the differential WBC counts between the groups, discriminant analysis was performed using the five differential WBC counts as covariates and the disease groups as the categorical variable, followed by a canonical plot of the WBC differential counts by disease groups. Statistical analyses were performed using R Statistical Software (version 4.0.5; R Foundation, Vienna, Austria) and JMP Pro 16.0 (SAS Institute Inc., NC, USA).

Ethics

This study was approved by the Institutional Review Board of the Tohoku University Hospital School of Medicine (Approval No. 2020-4-072). All procedures were performed in accordance with the current version of the Declaration of Helsinki, revised in 2013. Written informed consent from the HCs was obtained from all enrolled volunteers. Written informed consent from the patient group was waived by the Institutional Review Board, and informed consent was secured by an opt-out manner.

Results

Participants

A total of 2852 patients (1271 men and 1581 women) who visited our department with miscellaneous complaints during the study period were initially recruited. After excluding ineligible patients based on the inclusion criteria, we enrolled 228 adult patients aged <65 years (67 men and 161 women) without disease-specific objective diagnostic findings after comprehensive screening diagnostic tests and who were subsequently diagnosed with one or more of the aforementioned exclusion diagnoses. More specifically, patients with prolonged fatigability were confirmed to be negative for serum immunoglobulin M (IgM) antibodies for Epstein–Barr virus and cytomegalovirus,12 while patients with prolonged slight fever were confirmed to be negative for blood cultures. Data were also obtained from 228 age- and sex-matched HCs (67 men and 161 women) without notable medical histories from among the whole 2492 healthy volunteers.

The demographic features and measured counts for each blood cell subtype in the symptomatic and HC groups are summarized in Table 1. Using the statistical significance of $p<0.005$, only circulating monocyte count ($p=0.0014$), basophil count ($p=0.0023$), NLR ($p=0.0042$), and MLR ($p<0.0001$) differ significantly between the groups. Spearman’s $\rho$ value between age and MLR was $-0.06$ ($p=0.3304$) in HCs and $+0.03$ ($p=0.6307$) in the symptomatic group, suggesting that MLR was not influenced by age. The histograms for the MLR values in the 2492 healthy patients (Figure 2(a)) and 228 patients with unexplained physical complaints (Figure 2(b)) showed a higher range of values in the symptomatic group. Among the 2492 healthy population, 94.1% had MLR $<0.25$.

MLR and nonfocal physical symptoms

Next, the clinical symptoms of symptomatic patients with elevated MLR levels were investigated. In total, 26 patients in the symptomatic group were with an MLR of $\geq 0.25$. The symptoms in these 26 patients included prolonged fatigability (10 patients, 38.5%), prolonged slight fever (7, 26.9%), widespread pain (8, 30.8%), and abnormal bowel habits with frequent diarrhea (6, 23.1%). The clinical profiles of the symptomatic patients with MLR $\geq 0.25$ ($n=26$) are listed in Table 2. In contrast to the patients with elevated MLR, none of the 13 patients with low MLR values ($<0.10$) showed

\[ NLR = \frac{\text{Neutrophil count}[\mu L]}{\text{Lymphocyte count}[\mu L]} \]

\[ PLR = \frac{\text{Platelet count}[\mu L]}{\text{Lymphocyte count}[\mu L]} \]

\[ MLR = \frac{\text{Monocyte count}[\mu L]}{\text{Lymphocyte count}[\mu L]} \]
### Table 1. Demographic and laboratory features of the symptomatic and HC groups.

|                      | HCs (n = 228) | Symptomatic (n = 228) | Effect size | p-value |
|----------------------|---------------|-----------------------|-------------|---------|
| Male:female          | 67:161        | 67:161                | 0.00 (φ)    | 1.0000  |
| Age (years)a         | 30 (23–37)    | 30 (23–38)            | 0.01 (r)    | 0.9018  |
| TLC (/μL)a           | 5460 (4580–6400) | 5680 (4710–6615) | 0.06 (r)    | 0.2143  |
| DLC (/μL)a           |               |                       |             |         |
| Neutrophil           | 3160 (2460–3840) | 3390 (2720–4140) | 0.09 (r)    | 0.0479  |
| Lymphocyte           | 1780 (1560–2150) | 1710 (1450–2080) | 0.10 (r)    | 0.0325  |
| Monocyte             | 260 (210–340)  | 300 (240–350)         | 0.15 (r)    | 0.0014  |
| Eosinophil           | 130 (70–210)   | 110 (70–190)          | 0.09 (r)    | 0.0634  |
| Basophil             | 30 (20–40)     | 30 (20–50)            | 0.14 (r)    | 0.0023  |
| RBC count (10^6/μL)a | 460 (437–498)  | 461 (432–503)         | 0.01 (r)    | 0.8954  |
| Platelet (10^3/μL)a  | 248 (212–288)  | 251 (211–280)         | 0.01 (r)    | 0.7716  |
| Derived ratios       |               |                       |             |         |
| NLR                  | 1.73 (1.33–2.24) | 1.90 (1.43–2.51) | 0.13 (r)    | 0.0042  |
| PLR                  | 135 (108–176)  | 146 (117–175)         | 0.08 (r)    | 0.0727  |
| MLR                  | 0.146 (0.114–0.185) | 0.171 (0.135–0.211) | 0.20 (r)    | <0.0001 |

HC: healthy controls; TLC: total leukocyte count; DLC: differential leukocyte count; RBC: red blood cell; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio.

Symptomatic group comprised younger adults aged < 65 years with unexplained physical symptoms and with normal serum CRP levels.

*aMedian and interquartile range (25–75 percentile).*

---

**Figure 2.** Histograms of MLR values in the symptomatic and HC groups. Histograms of MLR values in the (a) healthy population (n = 2492), (b) age- and sex-matched HC and symptomatic patients, and (c) symptomatic group divided by the presence of nonfocal physical complaints, are shown. The distributions are positively skewed in both the symptomatic and HC groups and are higher in the symptomatic group. Within the 228 patients in symptomatic group, 63 patients with unexplained nonfocal physical complaints show higher MLR values compared to 165 patients with a single unexplained focal symptom.

HC: healthy control; MLR: monocyte-to-lymphocyte ratio.
fatigability, slight fever, widespread pain, or abnormal bowel habits (0.0% for all symptoms).

The histograms of MLR in symptomatic patients with unexplained single focal complaints and those with nonfocal physical complaints are shown in Figure 2(c). Patients with unexplained nonfocal physical symptoms showed higher MLRs. The prevalence of nonfocal physical symptoms in the subgroups with MLR values $\geq 0.25$, $0.20–0.25$, $0.15–0.20$, $0.10–0.15$, and $<0.10$ was 38.5% ($n=23/61$), 39.0% ($n=16/41$), 23.1% ($n=18/78$), 8.6% ($n=6/70$), and 0.0% ($n=0/13$), respectively. The distributions of MLR in the presence of the aforementioned characteristic conditions are shown in Figure 3. The basophil count in 228 symptomatic patients was not associated with any of the above symptoms.

**Canonical plot with differential WBC counts**

Based on the above findings that the profiles of the differential WBC counts may differ according to the clinical manifestations of symptomatic patients without known disease causes, a two-dimensional canonical plot was derived from discriminant analysis, which employed differential WBC counts as covariates and disease group as the categorical variable (Figure 4). The results did not differ between linear and quadratic discriminant analysis. The canonical plot showed a clear separation of the 95% confidence ellipse for symptomatic patients with nonfocal physical symptoms ($n=63$) from those for symptomatic patients with a single focal complaint ($n=165$) and for HCs ($n=228$).

**Discussion**

This study examined the WBC count profiles of patients with physical complaints without certain causes after comprehensive screening diagnostic examinations. The results showed that the counts of most types of blood cells did not differ between healthy volunteers and patients with unexplained symptoms.

### Table 2. Characteristics of 26 patients with unexplained physical symptoms and with MLR $>0.25$.

| Age, sex | MLR  | Prolonged fatigue | Fever | Widespread pain | Diarrhea | ANSD | Others |
|----------|------|-------------------|-------|-----------------|---------|------|--------|
| 40s, F   | 0.500| –                 | –     | +               | +       | –    | Dysphagia, depressed state |
| 20s, F   | 0.417| +                 | –     | –               | +       | +    | Sleepiness, vertigo, panic disorder |
| 20s, M   | 0.400| +                 | –     | –               | –       | –    | Depressed state |
| 10s, M   | 0.384| –                 | –     | –               | –       | +    | Panic disorder, hypertension |
| 20s, F   | 0.382| –                 | +     | –               | –       | –    | |
| 20s, F   | 0.317| –                 | +     | –               | –       | –    | Tremor in the hands |
| 30s, F   | 0.310| +                 | –     | –               | –       | +    | Vertigo |
| 40s, F   | 0.309| –                 | –     | –               | –       | +    | Chest pain, dyspnea, cough, headache, depressed state |
| 40s, M   | 0.302| –                 | –     | +               | +       | +    | Palpitation, sweating, panic disorder |
| 40s, F   | 0.299| –                 | +     | +               | –       | –    | Headache, arthralgia |
| 20s, M   | 0.294| –                 | –     | –               | –       | –    | Leg paina |
| 30s, M   | 0.289| +                 | –     | –               | –       | –    | Vertigo, depressed state |
| 20s, M   | 0.284| –                 | –     | +               | –       | –    | Palpitation, BPD |
| 30s, F   | 0.282| –                 | –     | +               | –       | –    | Abdominal pain, BPD |
| 30s, F   | 0.282| –                 | –     | +               | –       | –    | BPD |
| 10s, F   | 0.267| +                 | –     | –               | –       | –    | |
| 40s, F   | 0.266| –                 | –     | –               | –       | –    | Focal pain in hip jointa |
| 30s, M   | 0.265| +                 | –     | –               | –       | –    | |
| 20s, M   | 0.263| –                 | +     | –               | –       | –    | Panic disorder |
| 20s, M   | 0.260| +                 | –     | –               | –       | –    | Depressed state |
| 10s, F   | 0.259| –                 | –     | –               | –       | –    | Headache, sleepiness, social withdrawal |
| 40s, F   | 0.259| –                 | –     | +               | –       | –    | |
| 20s, F   | 0.259| +                 | –     | –               | –       | –    | Sleepiness, vertigo, depressed state |
| 10s, F   | 0.256| –                 | –     | –               | –       | –    | |
| 40s, F   | 0.253| –                 | –     | +               | –       | –    | Palpitations, panic disordera |
| 50s, F   | 0.252| +                 | +     | –               | –       | –    | |
| Rate     | –    | 38.5%             | 26.9% | 30.8%           | 23.1%   | 15.4% | |

MLR: monocyte-to-lymphocyte ratio; ANSD: autonomic nervous system dysfunction; BPD: borderline personality disorder.

*aThese three patients were classified into those with unexplained single focal physical symptom.*
physical complaints. Only MLR was slightly higher in the patient group. In particular, patients with an MLR > 0.25 (n = 26, 11.4%) were likely to also show nonfocal physical complaints with uncertain causes, with characteristic symptoms including fatigability, prolonged slight fever, and widespread pain. In contrast to the symptomatic patients, only 5.9% of the 2492 healthy participants showed MLR values > 0.25. Although the statistical difference was not strong, these findings implied that a high MLR value may be associated with the development of unexplained nonfocal physical complaints.

Currently, the exact role and clinical significance of circulating monocytes in peripheral blood remain largely uncertain. Circulating monocytes and differentiated cells in peripheral tissues protect the host from intruding microbial pathogens and clear waste products on tissue damage.13,14 Thus, invasion by undiagnosed microbial pathogens may explain the elevated MLR in some patients with unexplained physical complaints. However, all enrolled patients in this study had normal serum CRP levels and had normal findings on comprehensive diagnostic screening tests, including antibody tests for Epstein–Barr virus, blood cultures,
Thus, systemic infectious diseases were less likely. Additional studies are needed to determine whether an elevation in MLR could play a role in the development of the aforementioned nonfocal conditions, such as fatigue, slight fever, or widespread pain.

Another thing to be discussed is the potential roles of elevations in the NLR and basophil count, both of which were observed in this study, among patients with chronic complaints. An elevated NLR has been considered to reflect the presence of systemic inflammation from before, but the exact role and interpretation of an elevated NLR remain undetermined. A previous study suggested that elevated NLR might be associated with increased mortality rate among medical inpatients with multiple chronic conditions. A least abundance of the basophils among WBC subpopulations and its phenotypic resemblance to mast cells could have made research on basophils difficult. Meanwhile, there are several reports mentioning the potential roles of basophils in the early stage of some allergic, inflammatory, and autoimmune-related conditions. Most of the previous studies agree that the primary role of basophils would be modulatory actions, rather than effector actions. These facts may imply the possible presence of a prolonged mild inflammation that is undetected by the serum CRP levels in patients with unexplained prolonged physical or mental conditions. Future studies are needed to determine the potential roles of elevated NLR and basophils in the development of unexplained transdiagnostic conditions and the deterioration in the outcomes of physical and mental conditions.

The blood cell count profiles did not differ significantly between healthy volunteers and patients with physical complaints without known causes. However, some patients with whole-body CT imaging, and other relevant diagnostic tests. Thus, systemic infectious diseases were less likely.

**Figure 4.** Canonical plots for discriminant analyses of WBC differential counts by disease group. Canonical plots by discriminant analysis, using the five differential leukocyte counts as covariates and disease groups as the categorical variable. The obtained plot shows a clear separation of the 95% confidence ellipses between patients with focal and nonfocal complaints. Each plot represents data from individual enrolled participants, while the filled ellipse represents the 95% confidence ellipse for the multivariate mean in each of the disease groups. The variable vectors show the correlations between the response variables and two dimensions of the canonical space. WBC: white blood cell; CL: confidence limit.
unexplained nonfocal physical symptoms, such as fatigability, slight fever, or widespread pain, were more likely to show an elevated MLR of $\geq 0.25$. Further studies are needed to determine the possible role of elevated MLR in the development of unexplained nonfocal physical complaints.

Acknowledgements

The authors appreciate the volunteers who participated in the ToMMo project. The authors also thank the medical and administrative staff who participated in the collection of the data needed for this study.

Author contributions

T.A. performed statistical analyses and drafted the article. All authors contributed to data collection and critically revised the article. T.I., N.N., M.A., and A.H. supervised the study. All authors have read and approved the final article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics approval

This study was approved by the Institutional Review Board of the Tohoku University Hospital School of Medicine (Approval No. 2020-4-072). All processes were performed in accordance with the current version of the Declaration of Helsinki, as revised in 2013.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent from the HCs was obtained from all enrolled volunteers. Written informed consent from the patient group was waived by the Institutional Review Board, and informed consent was secured by an opt-out manner. Reason for obtaining opt-out informed consent from the patients group: This study enrolled all patients who visited the Department of General Medicine between 2018 and 2021, but written informed consent from the patients was started to be obtained from April 2019. Thus, the patients who visited the department between 2018 and 2019 were not obtained the written informed consent of this study. However, excluding these patients will make the sample size smaller and make the results of this study less reliable. Thus, the Institutional Review Board waived the written informed consent from the patient group for this study. We secured an opt-out period with the study protocol released on the homepage of the university for 6 months before starting this study.

ORCID iD

Tetsuya Akaishi https://orcid.org/0000-0001-6728-4966

References

1. Spillmann RC, McConkie-Rosell A, Pena L, et al. A window into living with an undiagnosed disease: illness narratives from the Undiagnosed Diseases Network. Orphanet J Rare Dis 2017; 12: 71.
2. Frances A and Chapman S. DSM-5 somatic symptom disorder mislabels medical illness as mental disorder. Aust N Z J Psychiatry 2013; 47(5): 483–484.
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–172.
4. Mueller T, Jerrentrup A, Bauer MJ, et al. Characteristics of patients contacting a center for undiagnosed and rare diseases. Orphanet J Rare Dis 2016; 11: 81.
5. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36(6): 339–356.
6. Tsai SY, Chen HJ, Lio CF, et al. Increased risk of chronic fatigue syndrome in patients with inflammatory bowel disease: a population-based retrospective cohort study. J Transl Med 2019; 17: 55.
7. Aaron LA, Burke MM and Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160: 221–227.
8. Farhangi MA, Keshavarz SA, Eshraghian M, et al. White blood cell count in women: relation to inflammatory biomarkers, hematological profiles, visceral adiposity, and other cardiovascular risk factors. J Health Popul Nutr 2013; 31(1): 58–64.
9. Hozawa A, Tanno K, Nakaya N, et al. Study profile of the Tohoku Medical Megabank Community-Based Cohort Study. J Epidemiol 2021; 31: 65–76.
10. Kuriyama S, Yaegashi N, Nagami F, et al. The Tohoku Medical Megabank Project: design and mission. J Epidemiol 2016; 26: 493–511.
11. Bender R and Lange S. Adjusting for multiple testing—when and how? J Clin Epidemiol 2001; 54: 343–349.
12. Shikova E, Reshko V, Kumanova A, et al. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic encephalomyelitis/chronic fatigue syndrome. J Med Virol 2020; 92: 3682–3688.
13. Karlmark KR, Tacke F and Dunay IR. Monocytes in health and disease—minireview. Eur J Microbiol Immunol 2012; 2(2): 97–102.
14. Guilliams M, Mildner A and Yona S. Developmental and functional heterogeneity of monocytes. Immunity 2018; 49: 595–613.
15. Isaac V, Wu CY, Huang CT, et al. Elevated neutrophil to lymphocyte ratio predicts mortality in medical inpatients with multiple chronic conditions. Medicine 2016; 95(23): e3832.
16. Brinn A and Stone J. Neutrophil-lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records. BMJ Open 2020; 10: e036859.
17. Siracusa MC, Kim BS, Spergel JM, et al. Basophils and allergic inflammation. J Allergy Clin Immunol 2013; 132: 789–801; quiz 788.
18. Cromheecke JL, Nguyen KT and Huston DP. Emerging role of human basophil biology in health and disease. Curr Allergy Asthma Rep 2014; 14(1): 408.
19. Pizzolo F, Castagna A, Olivieri O, et al. Basophil blood cell count is associated with enhanced factor II plasma coagulant activity and increased risk of mortality in patients with stable coronary artery disease: not only neutrophils as prognostic marker in ischemic heart disease. J Am Heart Assoc 2021; 10(5): e018243.
20. Akaishi T, Misu T, Fujihara K, et al. White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. *Sci Rep* 2021; 11: 22357.

21. Chirumbolo S, Bjørklund G, Sboarina A, et al. The role of basophils as innate immune regulatory cells in allergy and immunotherapy. *Hum Vaccin Immunother* 2018; 14: 815–831.

22. Yang J, Zhang L, Yu C, et al. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. *Biomark Res* 2014; 2: 1.

23. van de Wouw M, Sichetti M, Long-Smith CM, et al. Acute stress increases monocyte levels and modulates receptor expression in healthy females. *Brain Behav Immun* 2021; 94: 463–468.

24. Kim JH, Lee YJ and Park B. Higher monocyte count with normal white blood cell count is positively associated with 10-year cardiovascular disease risk determined by Framingham risk score among community-dwelling Korean individuals. *Medicine* 2019; 98(17): e15340.

25. Kim KI, Lee J, Heo NJ, et al. Differential white blood cell count and all-cause mortality in the Korean elderly. *Exp Gerontol* 2013; 48(2): 103–108.

26. Zeynalova S, Bucksch K, Scholz M, et al. Monocyte subtype counts are associated with 10-year cardiovascular disease risk as determined by the Framingham Risk Score among subjects of the LIFE-adult study. *PLoS ONE* 2021; 16(3): e0247480.

27. Akaishi T, Takahashi T and Nakashima I. Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis. *J Neuroimmunol* 2018; 319: 37–40.